Be Prepared to Treat and Prevent VTE Due to Cancer

June 2020

You’ll continue to see a shift toward direct oral anticoagulants (Eliquis, etc) for cancer-associated venous thromboembolism (VTE).

For years, we’ve been using a low-molecular-weight heparin (LMWH), such as enoxaparin...with warfarin as an alternative.

But evidence with DOACs is stacking up for VTE due to cancer.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber's Letter includes:

12 issues every year, with brief articles about new meds and guidelines
48+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Practice Help Patients and Staff Understand Test Results
Dermatology Manage Skin Irritation Due to Handwashing
Anticoagulants Be Prepared to Treat and Prevent VTE Due to Cancer
Infectious Diseases Put Treatments for COVID-19 in Perspective
Immunizations Keep Immunizations on Track During COVID-19
Poison Prevention Provide Strategies to Prevent Poisonings
Infectious Diseases Settle Debate About Vancomycin or Fidaxomicin for C. diff
Allergic Reactions Address Barriers to Getting Epinephrine for Anaphylaxis
Practice Weigh the Situation When Patients Ask About Expiration Dates
Infectious Diseases Stay on Top of Inpatient Treatment Options for COVID-19
New Drugs Explain Why IV Cetirizine Shouldn’t Be on Formulary